“COST-EFFECTIVENESS OF BEVACIZUMAB AND RANIBIZUMAB AS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR PATIENTS WITH EYE DISORDERS: A SYSTEMATIC REVIEW” (2024) Kartika Jurnal Ilmiah Farmasi, 9(1), pp. 37–53. doi:10.26874/kjif.v9i1.658.